These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 6488194)
21. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322 [TBL] [Abstract][Full Text] [Related]
22. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Anderson CP; Reynolds CP Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530 [TBL] [Abstract][Full Text] [Related]
23. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434 [TBL] [Abstract][Full Text] [Related]
24. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Dusre L; Mimnaugh EG; Myers CE; Sinha BK Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960 [TBL] [Abstract][Full Text] [Related]
25. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369 [No Abstract] [Full Text] [Related]
26. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Andrews PA; Murphy MP; Howell SB Mol Pharmacol; 1986 Dec; 30(6):643-50. PubMed ID: 3785141 [TBL] [Abstract][Full Text] [Related]
28. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339 [TBL] [Abstract][Full Text] [Related]
29. Isolation and characterization of a Chinese hamster ovary cell line resistant to bifunctional nitrogen mustards. Robson CN; Alexander J; Harris AL; Hickson ID Cancer Res; 1986 Dec; 46(12 Pt 1):6290-4. PubMed ID: 3779647 [TBL] [Abstract][Full Text] [Related]
30. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL). Pu Q; Bianchi P; Bezwoda WR Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327 [TBL] [Abstract][Full Text] [Related]
31. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA; Hosking LK; Hill BT Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800 [TBL] [Abstract][Full Text] [Related]
32. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Chen G; Zeller WJ Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864 [TBL] [Abstract][Full Text] [Related]
33. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer. Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140 [TBL] [Abstract][Full Text] [Related]
34. Selective enhancement of hypoxic cell killing by melphalan via thiol depletion: in vitro studies with hypoxic cell sensitizers and buthionine sulfoximine. Roizin-Towle L J Natl Cancer Inst; 1985 Jan; 74(1):151-7. PubMed ID: 3155814 [TBL] [Abstract][Full Text] [Related]
35. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells. Oguchi H; Kikkawa F; Kojima M; Maeda O; Mizuno K; Suganuma N; Kawai M; Tomoda Y Anticancer Res; 1994; 14(1A):193-200. PubMed ID: 7909418 [TBL] [Abstract][Full Text] [Related]
36. Flow cytometric analysis of DNA damage and repair in the cells resistant to alkylating agents. Frankfurt OS; Seckinger D; Sugarbaker EV Cancer Res; 1990 Aug; 50(15):4453-7. PubMed ID: 2369722 [TBL] [Abstract][Full Text] [Related]
37. Glutathione depletion in human T lymphocytes: analysis of activation-associated gene expression and the stress response. Walsh AC; Michaud SG; Malossi JA; Lawrence DA Toxicol Appl Pharmacol; 1995 Aug; 133(2):249-61. PubMed ID: 7645021 [TBL] [Abstract][Full Text] [Related]
38. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity. Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071 [TBL] [Abstract][Full Text] [Related]
39. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Goddard P; Valenti M; Kelland LR Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]